人淋巴母细胞干扰素对晚期肾细胞癌的抗肿瘤作用。
Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma.
作者信息
Fujita T, Asano H, Naide Y, Ono Y, Ohshima S, Suzuki K, Aso Y, Ariyoshi Y, Fukushima M, Ota K
机构信息
Department of Urology, Nagoya Memorial Hospital, Japan.
出版信息
J Urol. 1988 Feb;139(2):256-8. doi: 10.1016/s0022-5347(17)42380-9.
Human lymphoblastoid interferon alpha was administered intramuscularly at a dose of 3 times 10(6) units per day to 25 patients with advanced renal cell carcinoma. Six patients (24.0 per cent) showed objective responses, including 2 with complete regression of tumors. Nine patients (37.5 per cent) showed disease stabilization, while the disease progressed in 9 others (37.5 per cent). All tumor responses (2 complete, 4 partial and 2 mixed responses) were seen in lung, skin and liver metastases in patients whose primary tumors had been removed. Mean time to response was 87 +/- 74 days (range 28 to 240 days) and mean duration of response was 6.5 +/- 6.4 months (range 1 to greater than 20 months). Human lymphoblastoid interferon alpha was a potential active antitumor agent in patients with advanced renal cell carcinoma.
对25例晚期肾细胞癌患者，每天肌肉注射人淋巴母细胞干扰素α，剂量为3×10⁶单位。6例患者（24.0%）出现客观缓解，其中2例肿瘤完全消退。9例患者（37.5%）疾病稳定，另外9例（37.5%）疾病进展。所有肿瘤缓解（2例完全缓解、4例部分缓解和2例混合缓解）均见于原发肿瘤已切除患者的肺、皮肤和肝转移灶。平均缓解时间为87±74天（范围28至240天），平均缓解持续时间为6.5±6.4个月（范围1至大于20个月）。人淋巴母细胞干扰素α对晚期肾细胞癌患者是一种潜在的活性抗肿瘤药物。
Zotero 插件